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Abstract
Background: Mammalian angiotensin converting enzyme (ACE) plays a key role in blood pressure
regulation. Although multiple ACE-like proteins exist in non-mammalian organisms, to date only
one other ACE homologue, ACE2, has been identified in mammals.
Results: Here we report the identification and characterisation of the gene encoding a third
homologue of ACE, termed ACE3, in several mammalian genomes. The ACE3 gene is located on
the same chromosome downstream of the ACE gene. Multiple sequence alignment and molecular
modelling have been employed to characterise the predicted ACE3 protein. In mouse, rat, cow and
dog, the predicted protein has mutations in some of the critical residues involved in catalysis,
including the catalytic Glu in the HEXXH zinc binding motif which is Gln, and ESTs or reverse-
transcription PCR indicate that the gene is expressed. In humans, the predicted ACE3 protein has
an intact HEXXH motif, but there are other deletions and insertions in the gene and no ESTs have
been identified.
Conclusion: In the genomes of several mammalian species there is a gene that encodes a novel,
single domain ACE-like protein, ACE3. In mouse, rat, cow and dog ACE3, the catalytic Glu is
replaced by Gln in the putative zinc binding motif, indicating that in these species ACE3 would lack
catalytic activity as a zinc metalloprotease. In humans, no evidence was found that the ACE3 gene
is expressed and the presence of deletions and insertions in the sequence indicate that ACE3 is a
pseudogene.
Background
Angiotensin-converting enzyme (ACE; EC 3.4.15.1) is a
well-characterised zinc metallopeptidase that plays a key
role in the renin-angiotensin system [1]. Through cleavage
of a C-terminal dipeptide from angiotensin I to produce
the potent vasoconstrictor angiotensin II, and through
inactivation of the vasodilator bradykinin, ACE regulates
blood pressure and cardiovascular homeostasis. Inhibi-
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tors of ACE, such as captopril and lisinopril, are front line
therapeutics in a range of cardiovascular disorders, includ-
ing hypertension, congestive heart failure, left ventricular
hypertrophy and myocardial infarction [2].
ACE exists in two forms as a result of alternative use of
promoters within the same gene on human chromosome
17 and mouse chromosome 11: the larger, two domain
somatic ACE (1306 amino acids in humans) and the
smaller, single domain germinal ACE (701 amino acids in
humans) [3]. The latter is identical to the C-terminal
domain of somatic ACE, except for a unique region of 67
amino acids at its N-terminus. The two domains of
somatic ACE are catalytically active and each contains the
prototypical zinc binding motif HEXXH. In this motif, the
two His residues are two of the zinc ligands, the third
being a Glu on the C-terminal side of this motif [4]. The
Glu in the HEXXH motif is critically involved in catalysis,
binding the activated water molecule which initiates a
nucleophilic attack on the susceptible peptide bond in the
substrate. Recently, the separate three-dimensional struc-
tures of the C-domain and of the N-domain of ACE in
complex with the inhibitor lisinopril have been reported
[5,6]. Somatic and germinal ACE are synthesised with an
N-terminal signal sequence that is cleaved off in the
lumen of the endoplasmic reticulum and exist as type I
integral membrane proteins anchored to the plasma
membrane through a hydrophobic transmembrane
domain at the C-terminus.
In 2000, we and another group independently reported
the identification using genomics-based strategies of the
first human homologue of ACE, termed angiotensin-con-
verting enzyme-2 (ACE2) [7,8]. Like ACE, ACE2 is a type
1 integral membrane protein, however, ACE2 contains
only a single active site domain and consists of 805 amino
acids. The gene encoding ACE2 is located on the X chro-
mosome. ACE2 acts as a carboxypeptidase removing sin-
gle amino acids from the C-terminus of its substrates,
whereas ACE acts predominantly as a peptidyl dipeptidase
removing C-terminal dipeptides [1]. Studies from knock-
out mice indicate that ACE2 is an essential regulator of
heart function [9] and is involved in the tissue response to
injury [10]. ACE2 is also the receptor for the severe acute
respiratory syndrome (SARS) coronavirus [11]. Homol-
ogy modelling of the active site of ACE2 on the crystal
structure of the C-domain of ACE [12] and the subsequent
elucidation of the three-dimensional structure of the
extracellular domain of ACE2 [13] revealed that the cata-
lytic mechanism of ACE2 closely resembles that of ACE.
However, the substrate-binding pockets differ signifi-
cantly explaining the differences in substrate specificity
between the two enzymes and the failure of ACE inhibi-
tors to bind to and inhibit ACE2 [7,14].
ACE-like proteins also occur in non-mammalian species
[15,16].  Drosophila melanogaster has two functionally
active, single domain, soluble ACE-like proteins (termed
Ance and Acer) that share 36% amino acid sequence iden-
tity with human ACE [17]. There are four other ACE-like
genes in D. melanogaster that encode proteins which are
predicted to be catalytically inactive as they lack critical
residues involved in zinc binding or catalysis [18]. In the
mosquito Anopheles gambiae there are 9 genes which code
for proteins with similarity to mammalian ACE [19],
while in Caenorhabditis elegans there is a single ACE-like
gene which also encodes a protein that is predicted to be
catalytically inactive [20]. Orthologues of ACE2 have been
described recently in a range of non-mammalian verte-
brates [21].
In this study we have identified and characterised a gene
in the genomes of several mammalian species that
encodes a novel, single domain ACE-like protein, that we
have termed ACE3. In mouse, rat, cow and dog ACE3, the
catalytic Glu is replaced by Gln (HQXXH) in the putative
zinc binding motif, indicating that in these species ACE3
would lack catalytic activity as a zinc metalloprotease. In
humans, we could find no evidence that the ACE3 gene is
expressed and the presence of deletions and insertions in
the sequence indicate that in humans ACE3 is a pseudog-
ene.
Results
Predicted ACE3 sequences in mouse, rat, dog and cow 
genomes
Blast searches using human somatic ACE against the
mouse genome and gene prediction programmes on the
NCBI and Ensembl databases identified a potential
homologous region on chromosome 11 (region E1)
downstream of the ACE gene.
The murine ACE3 gene consists of 2253 nucleotides
which encodes a predicted protein of 750 amino acids
(Fig. 1). Hydropathy analysis and transmembrane predic-
tion revealed two hydrophobic regions at the C-terminus
of the protein but no N-terminal signal peptide. The pre-
dicted amino acid sequence of murine ACE3 exhibits sig-
nificant homology to existing members of the ACE family
(Table 1), with the highest percentage identity (57%) to
the C-terminal domain of murine somatic ACE. In murine
ACE3, the HEMGH zinc binding motif characteristic of
other members of the ACE family was HQMGH (Fig. 1).
Predicted ACE3 sequences were identified also in the rat,
dog and cow genomes (Fig. 1). These sequences are more
closely related amongst each other than to ACE sharing
81%, 65% and 58% sequence identity with murine ACE3
in the case of rat, cow and dog, respectively. They all con-
tain the HQMGH motif characteristic of mouse ACE3,
however, neither the cow nor dog ACE3 predictedBMC Genomics 2007, 8:194 http://www.biomedcentral.com/1471-2164/8/194
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sequences contain an N-terminal signal peptide, although
the rat ACE3 predicted sequence does. Both the rat and
cow ACE3 sequences contain a predicted C-terminal
transmembrane region, whereas the dog ACE3 lacks such
a region.
Genomic sequence analysis of the murine ACE3 gene
The predicted murine ACE3 protein sequence was
mapped onto the genomic DNA and the intron-exon
boundaries determined. The murine ACE3 gene contains
13 exons, interspersed with 12 introns, spans 10.7 kb and
is located 5.5 kb downstream of the ACE gene (Fig. 2). In
the ACE3 gene, all the intron-exon junction sequences fol-
low the GT/GA rule (Table 2). Exon 8 contains the
HQMGH motif. The predicted ACE3 genes in rat, dog and
cow are also located on the same chromosome as ACE,
always downstream and in close proximity. A TblastN
search of ACE3 against the annotated mouse genome at
the NCBI only detected significant homology with ACE
(e-value: 6 × 10-79) and ACE2 (e-value: 6 × 10-10). No
other hit exists with an e-value of less than 0.01. This indi-
cates that there is no further closely related homologue of
ACE3, other than ACE and ACE2, in the mouse genome.
Expression of ACE3 in murine tissues
The expression of the mRNA encoding ACE3 was exam-
ined in several murine tissues. RT-PCR using selective
primers was performed on a panel of total RNA samples
from different tissues (Fig. 3). A transcript encoding ACE3
was detected in testis, heart and embryo, but not in a
range of other tissues, including, kidney, lung, and liver.
Although a larger RT-PCR product was identified in the
brain RNA sample, on sequencing this was found not to
correspond to ACE3.
Modelling of the substrate binding site of murine ACE3
The predicted murine ACE3 sequence was modelled on
the C-terminal domain of human somatic ACE [5]. Over-
Multiple sequence alignment of predicted ACE3 sequences from human, mouse, rat, cow and dog with human testicular ACE Figure 1
Multiple sequence alignment of predicted ACE3 sequences from human, mouse, rat, cow and dog with human 
testicular ACE. HEXXH motif indicated. Underlined are the predicted N-terminal signal sequences (human and rat ACE3) 
and C-terminal transmembrane regions (human, rat, mouse and cow ACE3), along with the known N-terminal signal sequence 
and C-terminal transmembrane region in testicular ACE. The human ACE3 sequence was restored by compensating for fbase 
deletion(s)/insertions and suppressing *stop codons. Positions of the forward and reverse RT-PCR primers are indicated by the 
arrows beneath the sequence. Accession numbers: Mouse XP_110936; Rat XP_573208; Dog XP_548034; Cow XP_600103.
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all, both the fold and active site in murine ACE3 are highly
conserved as compared to human ACE (Fig. 4). However,
several substitutions occur in the ACE3 predicted active
site, some of which are unique to ACE3 family members
(such as Glu384 to Gln and Asp415 to Ser) (Fig. 5). The
most significant substitution is unquestionably Glu384 to
Gln that replaces the catalytic Glu in the HEXXH zinc
binding motif. Comparison of residues surrounding the
proposed transition state of ACE [22,23] show why this
substitution could be so detrimental to the ability of ACE3
to act as a protease (Fig. 5). Ionized Glu384 is proposed to
stabilise the positively charged amine intermediate and
act as a proton acceptor/donor in the ACE enzyme mech-
anism. In addition to the Gln being a poor proton accep-
tor/donor in ACE3, its involvement is further
compromised by both the amide side chain atoms being
involved in hydrogen bonding to two neighbouring resi-
dues, substituted from Ala to Thr361 and Ser363, respec-
tively. Another important substitution is Asp415 to Ser
which affects zinc binding by interfering with the hydro-
gen bond network to His383, the first histidine residue in
the HEXXH zinc binding motif in testicular ACE.
Genomic sequence analysis of the human ACE3 gene
Blast searches using human somatic ACE against the
human genome and gene prediction programmes on the
Ensembl and NCBI databases identified a potential
homologous region on chromosome 17 (region q23), 30
kb downstream of the start site of the ACE gene. This third
potential human homologue of ACE was termed human
ACE3. According to current annotation for the ACE gene
(NCBI), a third ACE transcript exists. Alternative splicing
at the 3' coding region results in a frameshift and a C-ter-
minus that differs from the testicular ACE transcript in the
last three exons. Interestingly, this transcript variant com-
prises another 15 exons in the 3' non-coding region,
closely corresponding to the location of ACE3 (Fig. 6),
suggesting that the ancestral ACE3 may be a pseudogene
contained within the ACE gene.
The restored human ACE3 protein sequence (adjusted for
several base deletions/insertions causing frame shifts and
premature stop codons, see Fig. 1) shows strong conserva-
tion with ACE and other ACE3 sequences. It contains the
typical HEMGH zinc binding motif present in other mem-
bers of the ACE family and is 54% identical to the C-
domain of human ACE and 71% identical to the mouse
ACE3 catalytic domain, respectively. The ancestral ACE3
gene is predicted to contain at least 14 exons, interspersed
Table 2: Exon/intron boundary prediction for mouse ACE3.
Exon no. Exon size (bp) cDNA position 5' Splice donor Intron size (bp) 3' Splice acceptor Codon phase
1 264 1–264 catgGTGTGGT 385 CAGctgc 0
2 159 265–423 agagGTGACAG 261 CAGtaca 0
3 88 424–511 gcctGGTGAGCA 118 CAGACctcc 1
4 144 512–655 taatGGTAAGTG 740 TAGGAtaca 1
5 192 656–847 cctgGGTAAGGG 81 CAGGGaaca 1
6 98 848–945 ccagGTCAGTG 111 CAGcact 0
7 173 946–1118 cttcAGGTGTCTA 328 TAGGgtaa 2
8 224 1119–1342 ttcaGGTGATGG 152 CAGAGgagg 1
9 145 1343–1487 cttcAGGTGGGGA 1543 CAGGttga 2
10 99 1488–1586 tatcCGGTAAAGG 173 CAGAtact 2
11 123 1587–1709 cttgGGGTGAGTG 4092 TAGGgatc 2
12 185 1710–1894 tgaaGGTTGGAC 476 CAGAAaaaa 1
13 359 1895–2253
Lower case letters denote exon sequences; intron sequences are in upper case letters. The codon phase indicates the position of the intron in the 
codon triplet. O intron occurs between codons, I intron occurs after the first nucleotide, and II intron occurs after the second nucleotide in the 
codon.
Table 1: Percentage identity of the murine ACE family.
N-ACE C-ACE ACE2 ACE3
N-ACE 100 52 43 46
C-ACE 100 42 57
ACE2 100 39
ACE3 100
The catalytic peptidase M2 domains [44] of murine ACE (N- and C-
domain), ACE2 and ACE3 were aligned with each other using needle 
[37] and the percentage identity deduced.
Genomic mapping of mouse ACE3 to chromosome 11  region E1 Figure 2
Genomic mapping of mouse ACE3 to chromosome 
11 region E1. The exons encoding mouse ACE3 were 
mapped to the genomic sequence based on NCBI predictions 
for that gene.
5’ 3’
3’ 5’ ACE ACE3
5.5kb 10.7kb 21.3kbBMC Genomics 2007, 8:194 http://www.biomedcentral.com/1471-2164/8/194
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Proposed catalytic mechanism in ACE (top) in contrast to  predicted interactions in ACE3 (bottom) Figure 5
Proposed catalytic mechanism in ACE (top) in con-
trast to predicted interactions in ACE3 (bottom). 
Four amino acid substitutions (in boxes) are rationalised to 
cause loss of activity in murine ACE3 (see text). Note: 
Gln391 can be flipped and interact either way with the 
hydroxyl groups of Thr361 and Ser363 as the hydroxyl group 
can act either as a hydrogen bond donor or as an acceptor.
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RT-PCR analysis of ACE3 mRNA expression in various  murine tissues Figure 3
RT-PCR analysis of ACE3 mRNA expression in vari-
ous murine tissues. Total RNA (1 µg) from the indicated 
tissues was subjected to one step RT-PCR as described in 
Materials and Methods followed by electrophoresis on a 1% 
agarose gel. (A) mouse ACE3; (B) actin. Lanes are as follows: 
1, positive control (whole mouse RNA with primers for 
actin); 2, negative control (no RNA); 3, brain; 4, embryo; 5, 
heart; 6, kidney; 7, liver; 8, lung; 9, ovary; 10, spleen; 11, tes-
tis; 12, thymus.
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Model of murine ACE3 Figure 4
Model of murine ACE3. The murine ACE3 model (blue) is 
superimposed on the human testicular ACE structure 
(green) co-crystallised with lisinopril (yellow). The zinc ion 
(spacefill) is coordinated by the zinc binding residues (red). 
The chloride ions (Cl) of testicular ACE and the locations of 
the N- and C- termini are also shown. A loop missing in tes-
ticular ACE is modelled in red.
N
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with 13 introns and spans 13 kb (Fig. 6). All of the pre-
dicted intron-exon junction sequences follow the GT/GA
rule (data not shown). Hydropathy analysis and trans-
membrane prediction revealed two hydrophobic regions
at the C-terminus, in agreement with ACE3 from other
species, and an N-terminal signal peptide.
The human ACE3 gene sequence, however, has several
frame shifts and premature stop codons (see Fig. 1). For
example, there is a one base deletion directly after the
sequence encoding the HEMGH zinc binding motif that
causes a frameshift and a premature stop codon. To con-
firm this deletion, genomic DNA was isolated from 3 dif-
ferent human cell lines (Eahy926, Hek293, SH-SY5Y) and
PCR performed using primers flanking this region. In all
three cell lines sequencing of the PCR product confirmed
that there was a one base deletion directly after the codon
for the second His of the zinc binding motif (data not
shown).
RT-PCR was used in an attempt to identify potential
mRNA transcripts of human ACE3. However, RT-PCR
using various primer sets on an RNA panel that included
total RNA from human brain, heart, kidney, liver, lung,
testis, colon, small intestine, placenta and skeletal muscle
failed to identify a transcript. The specificity of the primers
was checked by using them to PCR genomic DNA
extracted from Hek293 cells from which they amplified a
band of the predicted size that corresponded to the
sequence of ACE3 (data not shown). To date, blast
searches of the EST databases has not identified any ESTs
for human ACE3. Thus, point mutations that give rise to
premature stop codons and the failure to identify RNA
transcripts or ESTs all suggest that human ACE3 is likely a
pseudogene.
Discussion
In this study we have identified and characterised the gene
encoding a third mammalian homologue of ACE, termed
ACE3. The properties of the predicted ACE3 protein
sequences in human, mouse, rat, dog and cow are sum-
marised in Table 3. ACE3 in the mouse, rat, cow and dog
all contain Gln rather than Glu within the HQMGH
motif. The Glu residue is 100% conserved in all other ACE
(M2) family members and the MA (HEXXH containing)
clan of metalloproteases and is critically involved in catal-
ysis [24]. When this Glu was mutated to Gln in either
endopeptidase-24.15 [25] or ACE (Elliot, Duff, Jackson &
Hooper, unpublished) enzyme activity was completely
abolished. Another important substitution in murine
ACE3 is Asp415 to Ser which affects zinc binding by inter-
fering with the hydrogen bond network to the first histi-
dine residue in the HEXXH zinc binding motif. This
residue is conserved among vertebrate ACEs and in other
metalloproteases, corresponding to Asp650 in neprilysin
(M13 family) and Asp170 in thermolysin (M4 family). In
both ACE and neprilysin, this Asp was shown to be critical
for catalytic activity [26,27]. Due to these critical residues
being mutated in ACE3, it is likely that in mouse, rat, cow
and dog ACE3 will not be functional as a protease.
Although the ACE3 sequences in mouse, rat and cow all
possess C-terminal hydrophobic regions, only the rat
ACE3 sequence is predicted to contain an N-terminal sig-
nal peptide which would direct the nascent protein into
the lumen of the endoplasmic reticulum and then poten-
tially to the cell surface as is the case for ACE and ACE2.
ESTs for mouse, rat and cow ACE3 have been identified in
the databases and RT-PCR of multiple tissues revealed a
transcript for ACE3 in mouse heart and testis. In addition,
a recent proteomic analysis of murine sperm regions that
mediate sperm-egg interactions, reported the identifica-
tion of a protein with the same gene locus (LOC217246)
as ACE3 [28]. Thus, the available data suggest that ACE3
in mouse, rat and cow is expressed, but lacks protease
activity.
Within another zinc metalloprotease family, the ADAM (a
disintegrin and metalloprotease) family, several members
have subtle or more complete mutation of the HEXXH
motif [29]. For example, in ADAM4 the Glu is mutated to
Ala, while in ADAM29 it is His. Interestingly many of
these catalytically inactive members of the ADAM family
are present exclusively in the testis, where some have crit-
ical roles in fertilisation [29]. It remains to be determined
whether ACE3 has a role to play in fertilisation, although
the recent report of its presence in membrane vesicles
Gene structure of the human ACE3 gene Figure 6
Gene structure of the human ACE3 gene. The 
restored ancestral ACE3 is compared to three known ACE 
transcripts (somatic ACE (sACE), testicular ACE (tACE) and 
ACE isoform 3). ACE3 can be partly reconstructed from the 
ACE isoform 3 transcript. For clarity, only relevant exons are 
shown. Exons (black), introns (grey). Exons numbered 
according to NCBI gene annotation (ACE) and by compari-
son to other ACE3 sequences (ACE3). Individual ACE3 
exons are identical to isoform 3 except for exons 2 and 11 
(both have extra base pairs). Exons 28, 31 and 35 are not 
part of ACE3 (non-ACE like exons). Exons 1, 4 and part of 
exon 2 are spliced out in the isoform 3 transcript. * indicates 
stop codons; ** restored ACE3 stop codon (adapted from 
NCBI GeneID:1636).
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released by the acrosome reaction [28] is suggestive of
such a role. There is a further parallel between the ADAM
family members and ACE3, in that a large number of the
ADAMs present in the mouse genome are pseudogenes in
humans [29]. In the present study we could find no evi-
dence for human ACE3 to be expressed and the presence
in the gene of multiple base insertions and deletions
would, if expressed, generate a severely truncated protein
lacking residues that are critical for zinc binding and/or
catalysis in ACE and ACE2 [5,12,13]. This, and the locali-
sation of ACE3 within the ACE gene, point to ACE3 being
a pseudogene in humans.
Traditional, non-processed or duplicated pseudogenes
characteristically contain introns as they are duplications
of the genomic DNA, whereas processed or retrotrans-
posed pseudogenes are duplicated from RNA and lack
introns [30]. In addition, non-processed pseudogenes are
usually adjacent to their original functional copies. As
human ACE3 contains introns and is localised to the same
region of the genome as ACE, it appears to be a non-proc-
essed pseudogene. Such non-processed pseudogenes are
often silenced by point mutations, insertions or deletions,
as seen in human ACE3. This 'pseudogenization' of genes
in humans, as seen here with ACE3, results in the human
degradome containing only 561 functional genes, while
the mouse degradome is larger with 641 genes [31]. Inter-
estingly, many of these additional mouse genes are
involved in fertilisation and immunity.
While the ACE3 gene being located on the same chromo-
some just downstream of the ACE gene in all five genomes
analysed may just reflect an evolutionary relationship, it is
possible that this location alongside the ACE gene may
reflect a potential functional role at the genomic level, as
pseudogenes can regulate the expression of a related gene.
For example, the makorin1 protein is evolutionarily con-
served from nematodes to mammals and encodes an RNA
binding protein [32]. Normally makorin1 is expressed
throughout the animal but the disruption of the
makorin1 pseudogene markedly reduced the expression
of the makorin1 gene. This implies that for normal expres-
sion of makorin1, the presence of the RNA for the
makorin1 pseudogene is required. However, it should be
noted that a subsequent report failed to replicate this find-
ing [33] and the technical problems associated with such
studies are discussed more fully in [34]. Thus it is possible,
but remains to be determined, that the ACE3 gene may
regulate the expression of the ACE gene.
Conclusion
Multiple ACE-like genes have been identified in a range of
non-mammalian species and here we report the identifi-
cation and characterisation of a third ACE-like gene in the
genomes of several mammalian species. This gene
encodes a novel, single domain ACE-like protein, ACE3.
In the mouse, rat, cow and dog, where there is evidence
that ACE3 is expressed, the catalytic Glu is replaced by Gln
in the putative zinc binding motif, indicating that in these
species ACE3 would lack catalytic activity as a zinc metal-
loprotease. In humans, although the predicted ACE3 pro-
tein would contain an intact HEXXH zinc binding motif,
no evidence was found for the expression of the gene. This
lack of expression, along with the presence of deletions
and insertions in the sequence, indicate that in humans
ACE3 is a pseudogene.
Methods
Bioinformatics Analysis
Blast searches for potential ACE3 sequences using human
somatic ACE were performed against the mouse genome
and gene prediction programmes on the NCBI [35] and
Ensembl [36] databases. According to NCBI annotations,
the alternate Celera genome assembly is composed of
DNA from five different mouse strains: A/J, DBA/2J,
129X1/SvJ, 129S1/SvImJ and C57BL/6J, whereas the refer-
ence assembly is based on C57BL/6J. Sequences used for
bioinformatics sequence analysis and homology model-
ling were obtained from the NCBI RefSeq database.
Sequence analysis was performed using the Emboss soft-
Table 3: Comparison of the ACE3 sequences.
Species Length (amino acids) Zinc-binding motif Signal peptide TM region EST
Human 737§ HEMGH X
Mouse 750 HQMGH X
Rat 732 HQMGH
Dog 602 HQMGH X X X
Cow 738 HQMGH X
§refers to restored ancestral sequence as shown in Fig. 1.
9 9
9 9
9 9 9
9 9BMC Genomics 2007, 8:194 http://www.biomedcentral.com/1471-2164/8/194
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ware suite [37], Clustal W [38] and 3DCoffee [39].
Hydropathy analysis was performed as described [40].
Transmembrane and signal peptide regions were pre-
dicted using TMpred [41] and SignalP [42], respectively.
Homology modelling of mouse ACE3 was undertaken
with the SWISS-MODEL software [43] based on its align-
ment to the human testicular ACE template (PDB code
1o86).
Reverse transcription-PCR
Human and murine (from Swiss Webster mice) total RNA
was from Ambion (Europe) Ltd. (Huntingdon, UK).
Genomic DNA was isolated from Eahy926, Hek293 and
SH-SY5Y cells using TRIzol (GE Biosciences). Reverse tran-
scription-PCR (RT-PCR) was performed with a one step
Titanium RT-PCR kit (BD Biosciences, Oxford, UK) with 1
µg of RNA and the appropriate forward and reverse prim-
ers at 50 pmol/µl. For mouse ACE3 the primers were: for-
ward 5'-GGGCGGGAAGTGGAGTGCCACA-3'; reverse 5'-
GTTGACCTCCTCCTCTGAATCCTGG-3'. For human
ACE3 the primers were: forward 5'-TCTGCCTGGAACT-
TCCCAGGACG-3'; reverse 5'-CCCATTTCGTGGAAAGAT-
GGAGAGCG-3'. For mouse actin the primers were:
forward 5'-GTGGGCCGCTCTAGGCACCAA-3'; reverse 5'-
CTCTTTGATGTCACGCACGATTTC-3'. After incubation at
50°C for 1 h and initial denaturation for 5 min at 94°C,
30 cycles of denaturation at 94°C for 1 min, annealing at
55°C for 1 min and extension at 68°C for 1 min, followed
by a final extension at 68°C for 2 min was performed.
Abbreviations
ACE, angiotensin converting enzyme; ADAM; a disin-
tegrin and metalloprotease; EST, expressed sequence tag;
RT-PCR, reverse transcription-PCR.
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